KOSDAQBiotech & Pharma200230

Telcon RF Pharmaceutical

₩1,782▼ 1.05%2026-11-18 close
Market Cap
₩16.9B
Turnover
₩9,440,626
Volume
5.3K
Shares out.
9.5M
PER
—
PBR
0.2×
EPS
-₩1,833
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Pharma Sales Growth Versus Persistent Quarterly Losses

Pharma now makes up over 80% of revenue and sales rose three straight years through 2025, yet operating losses and net losses attributable to controlling shareholders have continued for three consecutive quarters from Q1 to Q3 2026.

  1. 1

    Revenue for 2025 rose 14.0% year on year to KRW 43.2 billion, and operating profit of KRW 719 million returned the company to profit after a 2024 operating loss.

  2. 2

    The net loss attributable to controlling shareholders narrowed to KRW 11.5 billion in 2025 from KRW 26.3 billion in 2024.

  3. 3

    Q3 2026 revenue of KRW 27.5 billion was up 180.3% year on year, while the operating loss widened to KRW 3.03 billion.

  4. 4

    In 2026 the company offset its accumulated deficit through a 10-to-1 capital reduction and reorganized its capital through a third-party share issuance and debt-to-equity conversion of affiliate loans.

  5. 5

    Losses attributable to controlling shareholders over the last four quarters total KRW 17.4 billion, so no price-to-earnings ratio is calculated, while the stock trades well below its net asset value.

02

Business structure

Telcon RF Pharmaceutical was founded in 1999 and runs two businesses: pharmaceutical manufacturing and sales, and RF communication components. Pharmaceuticals accounted for 80.5% of 2025 revenue, up from 40.3% in 2021.

Pharma division sales were KRW 25.9 billion in 2023, KRW 26.9 billion in 2024 and KRW 34.7 billion in 2025, with the 2025 figure up about 29% from the prior year. The lead product is the gastrointestinal protectant Algicel Liquid (active ingredient sodium alginate), and other liquid formulations also expanded sales.

Per the company's 2025 product sales breakdown, these products were sold entirely in Korea. Production runs at a KGMP-certified in-house plant with a strength in liquid formulations, and tablets, pills and capsules can also be made.

The company said utilization of the plant reached 120% in 2025, leaving little spare capacity, so it is building palletizing equipment and a 2,000-cell high-rack warehouse. In RF, the main products are cable assemblies and connectors, which made up 19.55% of 2025 revenue.

Cable assemblies were 70.75% domestic and 29.25% export, and connectors 63.68% domestic and 36.32% export. In 2026 the company gained control of an affiliate and consolidated its subsidiaries, and in September 2025 it sold its stake in a former subsidiary. The largest shareholder group held 40.58% as of October 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩9.8B-₩8,655,775−0.1%
2025Q4₩13.3B₩2.6B19.7%
2026Q1₩9.7B-₩1.4B−14.7%
2026Q2₩28.9B-₩800M−2.8%
2026Q3₩27.5B-₩3B−11.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩27.8B-₩4.1B-₩42.1B−14.6%−50.0%41.7%
2023₩36.3B₩1B₩13.9B2.7%13.3%33.8%
2024₩37.9B-₩70,548,303-₩26.3B−0.2%−31.8%84.7%
2025₩43.2B₩700M-₩11.5B1.7%−10.6%44.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue rose from KRW 27.8 billion in 2022 to KRW 36.3 billion in 2023 (up 30.5%), KRW 37.9 billion in 2024 (up 4.3%) and KRW 43.2 billion in 2025 (up 14.0%). Revenue has grown for three straight years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Pharmaceutical sales, which rose about 29% in 2025, were the core of this growth and outpaced total revenue.

Operating profit moved from an operating loss of KRW 4.06 billion in 2022 (margin of -14.6%) to operating profit of KRW 965 million in 2023 (2.7%), back to an operating loss of KRW 70.55 million in 2024 (-0.2%), and then to operating profit of KRW 719 million in 2025 (1.7%).

Margins stayed in a narrow band even as revenue grew. Net loss attributable to controlling shareholders was KRW 42.1 billion in 2022, a profit of KRW 13.9 billion in 2023, a loss of KRW 26.3 billion in 2024 and a loss of KRW 11.5 billion in 2025, a narrower loss.

Net loss including non-controlling interests was KRW 26.5 billion in 2024 and KRW 11.4 billion in 2025, a different figure from the controlling-shareholder measure. The 2024 net loss was far larger than the operating loss, so non-operating items and tax lines in the notes to the annual report are worth checking.

The debt-to-equity ratio rose to 84.7% in 2024 and fell to 44.0% in 2025, when total equity was KRW 108.8 billion and total liabilities were KRW 47.8 billion. Operating cash flow turned positive in 2024 (KRW 1.22 billion) and 2025 (KRW 1.67 billion) after negative figures in 2022 and 2023.

On a quarterly basis, Q3 2025 revenue was KRW 9.82 billion with an operating loss of KRW 8.66 million and a controlling-shareholder net loss of KRW 4.88 billion. Q4 2025 revenue rose 35.6% to KRW 13.3 billion, with operating profit of KRW 2.63 billion and a controlling-shareholder net profit of KRW 9.85 billion.

Q1 2026 revenue fell 27.2% to KRW 9.7 billion and the company posted an operating loss of KRW 1.43 billion, while press reports put pharma sales at KRW 7.4 billion, or 76.5%, of that quarter. Q2 2026 revenue jumped 198.3% to KRW 28.9 billion and the operating loss narrowed to KRW 806 million.

Q3 2026 revenue of KRW 27.5 billion was up 180.3% year on year, but the operating loss widened to KRW 3.03 billion. Controlling-shareholder net losses over the last four quarters total KRW 17.4 billion.

How much the expanded consolidation scope contributed to the 2026 revenue jump should be checked in the annual report's consolidation notes.

05

Industry analysis

In pharmaceuticals, supply instability and shortages have become an industry-wide concern, and the company says it is responding by building a stable production and supply system. Demand growth for gastrointestinal protectants was cited as the main driver of 2025 results.

The company is developing specialized products for chronic-disease markets, including treatments for hyperkalemia in dialysis patients, as part of a strategy to reduce dependence on a few products.

On market position, the company says the dominance of its core products is gradually strengthening, but this is its own claim rather than a figure from independent market-share data.

The RF business was hurt by a downturn in telecom components, which is why management has built pharmaceuticals as its next growth engine. The shift to 5G has reduced base station demand and remains the main burden on RF.

Overseas demand has not disappeared, as the 5G small repeater contract disclosed in October 2026 involves domestic delivery followed by export to Japan. With pharma plant utilization at 120%, how quickly demand turns into revenue depends on how fast capacity is added.

The growing pharma segment and the weak RF segment together determine the direction of the overall business mix.

06

Outlook

The company aims to generate more than KRW 30 billion in annual revenue through process efficiency and logistics automation.

In December 2025 it said pharma sales should keep growing at double-digit rates the following year, and whether that is achieved should be checked against pharma revenue in the 2026 annual report.

On capacity, palletizing equipment and a 2,000-cell high-rack warehouse are under way, and a KRW 3.0 billion third-party share issue to fund facility expansion was decided in April 2026.

A KRW 5.0 billion third-party rights offering was completed in July 2026, which the company described as a step to tidy up intragroup equity links and ease financial burdens.

New contracts include a 5G wireless materials unit-price contract disclosed on October 2, 2026, worth about KRW 2.3 billion for October 1, 2026 to September 30, 2027, and a 5G small repeater supply contract disclosed on October 26, 2026, worth about KRW 3.6 billion for October 23, 2026 to March 10, 2027.

These amounts equal 5.34% and 8.26% of 2025 year-end revenue, respectively. The small repeater contract is paid 100% after delivery. Specific launch timing for the dialysis-related pipeline should be checked in future annual reports and disclosures.

07

Valuation

PER
—
PBR
0.2×
ROE
-18.4%
EPS
-₩1,833
BPS
₩9,239
Dividend per share
₩0

The price-to-earnings ratio is not calculated because controlling-shareholder net losses over the last four quarters total KRW 17.4 billion. The price-to-book ratio places the stock well below its net asset value, measured against controlling-shareholder equity of KRW 108.5 billion at end-2025.

The cash dividend yield is effectively nil. This structure shows how the market is weighing asset value against current earnings. Years in which operating profit returned to profit (2023 and 2025) support the case for recovery, while the operating losses in the first three quarters of 2026 point the other way.

The debt-to-equity ratio fell from 84.7% in 2024 to 44.0% in 2025, and operating cash flow was positive in 2025. The key variable for interpreting valuation is whether operating profit can stay positive over consecutive periods.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Revenue Up Three Straight Years

Revenue grew for three straight years from 2023 through 2025, and the KRW 43.2 billion in 2025 was the largest annual figure in the 2022 to 2025 span. Pharma sales rose about 29% in 2025, with demand for the Algicel Liquid gastrointestinal protectant line cited as the driver.

Plant utilization of 120% in 2025 shows demand exceeded production capacity, and the equipment investment is aimed at easing that constraint.

Improving Balance Sheet and Cash Flow

The debt-to-equity ratio fell from 84.7% in 2024 to 44.0% in 2025, with total equity of KRW 108.8 billion and total liabilities of KRW 47.8 billion at end-2025. Operating cash flow was negative in 2022 and 2023 but turned positive, at KRW 1.22 billion in 2024 and KRW 1.67 billion in 2025. A 10-to-1 capital reduction in 2026 offset the accumulated deficit and advanced the capital structure cleanup.

RF Single-Sales Contracts Disclosed

A 5G wireless materials unit-price contract disclosed on October 2, 2026 has a contract value of about KRW 2.3 billion. A 5G small repeater supply contract disclosed on October 26, 2026 is worth about KRW 3.6 billion and involves domestic delivery followed by export to Japan. The two contracts equal 5.34% and 8.26% of year-end 2025 revenue, offering a read on near-term RF order flow.

09

Bear factors

Quarterly Losses Persist

Operating losses and controlling-shareholder net losses have persisted for three consecutive quarters, from Q1 to Q3 2026. The Q3 2026 operating loss of KRW 3.03 billion was larger than the KRW 806 million loss in Q2. Revenue has grown, but converting it into profit remains the open challenge.

Weak Demand in RF

Lower base station demand following the shift to 5G leaves the RF segment in operating loss. RF accounted for 19.55% of 2025 revenue, led by cable assemblies and connectors. The two 5G contracts disclosed in October 2026 equal 5.34% and 8.26% of year-end 2025 revenue, and their terms run only to around 2027.

Equity Issuance and Intragroup Reshuffling

A third-party share issue to fund KRW 3.0 billion of facility spending was decided in April 2026, and a KRW 5.0 billion third-party rights offering was completed in July. The new shares are locked up for one year after listing.

During the same period, part of intragroup loans was converted into equity, and the company gained control of an affiliate in 2026, widening its consolidation scope. More shares and a changing intragroup structure raise questions of shareholder dilution and related-party oversight.

10

Risk factors

Concentration Risk

Pharmaceuticals made up 80.5% of 2025 revenue, so results depend heavily on demand and supply stability for a small number of gastrointestinal protectant products. Sales are concentrated in Korea, leaving the line exposed to changes in reimbursement pricing or prescribing conditions. The timing and revenue contribution of the specialized pipeline are difficult to gauge from public information.

Capacity and Capex Risk

With plant utilization at 120%, converting demand into revenue depends on completing the palletizing equipment and the 2,000-cell warehouse on schedule. Facility spending is being funded through share issuance, so the pace of spending and returns on that investment are open questions. Maintaining quality control standards during process changes is a precondition for stable results.

Financial and Governance Risk

Controlling-shareholder net losses over the last four quarters total KRW 17.4 billion, while total equity stood at KRW 108.8 billion at end-2025. Additional capital raises may be needed until profits recover.

Two third-party share issues in 2026 increased the share count, and the release of locked-up shares could add to the float. The largest shareholder group's 40.58% stake also shapes the trading structure.

11

What to watch next

  1. March 10, 2027

    End of the 5G small repeater supply contract period. Confirm delivery completion and settlement under the 100%-after-delivery payment terms through disclosures.

  2. Late March 2027

    Filing deadline for the 2026 annual report. Check full-year 2026 revenue and operating profit, whether pharma sales reached the target, and how the change in consolidation scope affected revenue.

  3. Mid-May 2027

    Filing deadline for the Q1 2027 quarterly report. Whether the streak of operating losses ends and whether pharma sales hold up on a quarterly basis are the key checks.

  4. Around July 2027

    Expected release of the one-year lock-up on the July 2026 third-party shares. Watch how the increase in tradable shares affects supply and demand.

  5. September 30, 2027

    End of the 5G wireless materials unit-price contract period. Check whether it is renewed and the trend in RF segment revenue.

12

Overall view

Telcon RF Pharmaceutical is shifting its business toward pharmaceuticals, with revenue rising for three straight years from 2023 through 2025. Operating profit returned to profit in 2025, and operating cash flow stayed positive after turning positive in 2024.

However, operating losses and controlling-shareholder net losses have persisted for three consecutive quarters from Q1 to Q3 2026, and controlling-shareholder net losses over the last four quarters total KRW 17.4 billion.

Q3 2026 revenue of KRW 27.5 billion was up sharply year on year, but the wider operating loss shows the gap between revenue scale and profitability. The balance sheet improved, with a debt-to-equity ratio of 44.0% and total equity of KRW 108.8 billion at end-2025.

Bullish factors are pharma sales growth, capacity investment and balance sheet repair, while bearish factors are persistent quarterly losses, weak RF demand and dilution from equity raises.

The next items to verify are whether the pharma sales target appears in the 2026 annual report, and how much the change in consolidation scope contributed to revenue. Whether operating profit turns positive on a quarterly basis is also a point to confirm in the Q1 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. view.asiae.co.kr
  2. mt.co.kr
  3. mt.co.kr
  4. mt.co.kr
  5. specialtimes.co.kr
  6. specialtimes.co.kr
  7. topstarnews.net
  8. m.news.nate.com
  9. datatooza.com
  10. comp.wisereport.co.kr
  11. comp.wisereport.co.kr
  12. jobkorea.co.kr
  13. dealsite.co.kr
  14. investing.com
  15. mydailybyte.com
  16. asiae.co.kr
  17. etoday.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis